Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâ€™s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	15Cr 13Cr 12Cr 11Cr 21Cr 1.45TCr 22Cr 146.39Cr 57Cr 713.51Cr 57Cr 56Cr 2.45TCr	P/E 2027 *	-	P/E 2028 *	-
Enterprise Value	13Cr 11Cr 10Cr 9.59Cr 18Cr 1.23TCr 19Cr 124.07Cr 49Cr 604.73Cr 48Cr 47Cr 2.08TCr	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	98.57%	Yield 2027 *	-	Yield 2028 *	-

17/06	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
17/06	Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026	CI
16/06	Assertio Holdings, Inc.(NasdaqCM:ASRT) dropped from S&P TMI Index	CI
16/06	Assertio Holdings, Inc.(NasdaqGM:ASRT) dropped from NASDAQ Composite Index	CI
16/06	Zydus Worldwide DMCC completed the acquisition of Assertio Holdings, Inc..	CI
13/05	Garda Therapeutics, Inc. cancelled the acquisition of Assertio Holdings, Inc..	CI
13/05	Zydus Worldwide DMCC entered into definitive agreement to acquire Assertio Holdings, Inc. for approximately $160 million.	CI
13/05	Assertio to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash	RE
13/05	Assertio Board Approves $23.50-Per-Share Sale to Zydus Worldwide DMCC	MT
13/05	Zydus to Acquire Assertio for $166.4 Million	DJ
09/05	Assertio Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
08/05	Assertio and Garda mutually agree to delay launch of tender offer	RE
05/05	Assertio and Garda mutually agree to postpone commencement of tender offer	RE

09/04	HC Wainwright Downgrades Assertio Holdings to Neutral From Buy, Adjusts Price Target to $18 From $35	MT
03/24/03	HC Wainwright Initiates Assertio Holdings at Buy With $4 Price Target	MT
12/24/12	Lake Street Adjusts Assertio Therapeutics' Price Target to $3 From $4, Maintains Buy Rating	MT
10/23/10	BWS Financial Adjusts Assertio Therapeutics' Price Target to $10 From $8, Keeps Buy Rating	MT
10/23/10	Lake Street Adjusts Assertio Therapeutics' Price Target to $9 From $8, Keeps Buy Rating	MT

17/06	Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027	BU
19/05	Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT	BU
13/05	Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash	BU
08/05	Assertio and Garda Mutually Agree to Delay Launch of Tender Offer	BU
05/05	Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer	BU

Director	Title	Age	Since
Ravi Yadavar BRD	Director/Board Member	26	16/06/2026
Punit Patel BRD	Director/Board Member	-	16/06/2026

Depomed Inc Share Price Nasdaq

Stocks

US2499081048

Pharmaceuticals

Valuation: Depomed Inc

Latest news : Depomed Inc

Last Transcript: Depomed Inc

Analysts' recommendations: Depomed Inc

Press Releases: Depomed Inc

Quotes and Performance

Managers and Directors: Depomed Inc

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DEPOMED INC	-9.45%	+3.54%	-	-	15Cr
ELI LILLY AND COMPANY	-2.06%	-0.91%	+50.41%	+162.42%	1,08500Cr
JOHNSON & JOHNSON	-0.77%	-1.10%	+62.65%	+60.80%	62TCr
ABBVIE INC.	-0.70%	-2.74%	+27.07%	+84.24%	44TCr
ROCHE HOLDING AG	+0.33%	-1.17%	+27.98%	+26.90%	33TCr
ASTRAZENECA PLC	-3.89%	-11.22%	+20.78%	+26.07%	28TCr
NOVARTIS AG	-0.02%	-2.85%	+25.27%	+44.88%	28TCr
NOVO NORDISK A/S	+0.66%	-1.42%	-29.26%	-39.30%	22TCr
AMGEN INC.	+0.06%	-1.08%	+20.68%	+61.30%	20TCr
GILEAD SCIENCES, INC.	-3.56%	+0.26%	+13.45%	+71.69%	17TCr
Average	-2.00%	-1.86%	+24.34%	+55.44%	40.24TCr
Weighted average by Cap.	-1.29%	-1.06%	+35.31%	+81.64%

	2027 *	2028 *
Net sales	-	-
Net income	4L 3L 3L 3L 6L 3.81Cr 6L 38.56L 15.14L 1.88Cr 15.02L 14.69L 6.46Cr	-
Net Debt	-	-